SecBot SecBot
SECBOTREPLAY Home › Report › LXRX

LXRX · Lexicon Pharmaceuticals filed an 8-K reporting the automatic conversion…

LEXICON PHARMACEUTICALS, INC. · 8-K filed Apr 30, 2026 at 16:05 ET

At the news

BEARISHIMPACT 6/10

8-K filed Apr 30, 2026 at 16:05 ET

Lexicon Pharmaceuticals filed an 8-K reporting the automatic conversion of all outstanding Series B Convertible Preferred Stock into 20.4M common shares, doubling authorized common shares to 900M, and stockholder approval of increased equity incentive plans. These actions significantly expand the company's share count and authorized capital, signaling potential future dilution but also providing flexibility for financing and employee retention.

  • All 408,434.7 shares of Series B Convertible Preferred Stock converted into 20,421,735 shares of common stock at a ratio of 50:1.
  • Authorized common stock increased from 450M to 900M shares via Seventh Amended and Restated Certificate of Incorporation.
  • 2026 Equity Incentive Plan approved, increasing share reserve from 75M to 90M shares.
  • 2026 Non-Employee Directors Equity Incentive Plan approved, increasing share reserve from 4M to 6M shares.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access